Profile data is unavailable for this security.
About the company
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. Its product candidates are derived from donor cells (allogeneic) rather than a patient's own cells (autologous) and are pre-manufactured, stored frozen and ready to ship to a patient's treatment location. Its lead product candidate, AlloNK, is being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs) in patients with autoimmune diseases and cancers, such as systemic lupus erythematosus (SLE), lupus nephritis (LN), RA, PV, the ANCA-associated vasculitis subtypes GPA/MPA, and B-NHL. AlloNK is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted mAbs in an ongoing Phase I/Ib trial in SLE with or without LN and a basket investigator-initiated trial (IIT) in multiple autoimmune indications.
- Revenue in USD (TTM)0.00
- Net income in USD-79.19m
- Incorporated2019
- Employees106.00
- LocationArtiva Biotherapeutics Inc5505 Morehouse DriveSAN DIEGO 92121United StatesUSA
- Phone+1 (858) 267-4467
- Fax+1 (302) 269-3855
- Websitehttps://www.artivabio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biomea Fusion Inc | 0.00 | -95.71m | 88.38m | 42.00 | -- | 4.76 | -- | -- | -2.39 | -2.39 | 0.00 | 0.2625 | 0.00 | -- | -- | 0.00 | -115.59 | -62.24 | -156.30 | -68.84 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -18.06 | -- | -- | -- |
| Precision BioSciences Inc | 698.00k | -83.60m | 89.07m | 67.00 | -- | 2.83 | -- | 127.61 | -8.40 | -8.40 | 0.0695 | 1.38 | 0.0057 | -- | 0.9001 | 6,462.96 | -67.76 | -26.22 | -76.07 | -33.68 | -- | -- | -11,977.36 | -87.80 | -- | -190.84 | 0.5736 | -- | 40.98 | 25.30 | 116.85 | -- | -59.31 | -- |
| Dogwood Therapeutics Inc | 0.00 | -39.98m | 91.26m | 12.00 | -- | -- | -- | -- | -24.92 | -24.92 | 0.00 | 33.75 | 0.00 | -- | -- | 0.00 | -81.05 | -52.48 | -84.58 | -55.93 | -- | -- | -- | -- | -- | -178.51 | 0.00 | -- | -- | -- | -142.90 | -- | -- | -- |
| Incannex Healthcare Inc | 12.00k | -47.87m | 93.17m | 12.00 | -- | 1.22 | -- | 7,764.11 | -0.9375 | -0.9375 | 0.0001 | 0.2215 | 0.0003 | -- | 0.0015 | 1,000.00 | -101.03 | -155.80 | -114.13 | -186.20 | -- | -- | -398,933.30 | -6,230.96 | -- | -43.84 | 0.00 | -- | 616.67 | -31.02 | -154.00 | -- | -- | -- |
| Anixa Biosciences Inc | 0.00 | -10.93m | 94.13m | 4.00 | -- | 6.14 | -- | -- | -0.3369 | -0.3369 | 0.00 | 0.4593 | 0.00 | -- | -- | 0.00 | -58.55 | -47.85 | -62.09 | -49.81 | -- | -- | -- | -8,381.30 | -- | -- | 0.00 | -- | -- | -- | 12.96 | -- | -- | -- |
| Equillium Inc | 4.39m | -24.42m | 95.60m | 35.00 | -- | 3.08 | -- | 21.77 | -0.632 | -0.632 | 0.1021 | 0.5099 | 0.1274 | -- | 1.71 | 125,485.70 | -70.81 | -44.86 | -89.09 | -58.85 | -- | -- | -555.94 | -164.30 | -- | -- | 0.00 | -- | 13.89 | -- | 39.51 | -- | 2.81 | -- |
| Artiva Biotherapeutics Inc | 0.00 | -79.19m | 98.18m | 106.00 | -- | 0.7598 | -- | -- | -3.25 | -3.25 | 0.00 | 5.26 | 0.00 | -- | -- | 0.00 | -42.29 | -44.57 | -45.24 | -51.09 | -- | -- | -- | -596.66 | -- | -- | 0.0006 | -- | -99.25 | -- | -127.62 | -- | 18.74 | -- |
| Cognition Therapeutics Inc | 0.00 | -27.99m | 98.87m | 25.00 | -- | 2.71 | -- | -- | -0.4816 | -0.4816 | 0.00 | 0.4138 | 0.00 | -- | -- | 0.00 | -78.86 | -59.00 | -108.44 | -75.05 | -- | -- | -- | -- | -- | -3,450.08 | 0.00 | -- | -- | -- | -31.73 | -- | -51.16 | -- |
| Actuate Therapeutics Inc | 0.00 | -24.12m | 100.64m | 10.00 | -- | 9.20 | -- | -- | -1.19 | -1.19 | 0.00 | 0.4705 | 0.00 | -- | -- | 0.00 | -150.86 | -- | -282.00 | -- | -- | -- | -- | -- | -- | -- | 0.0357 | -- | -- | -- | -10.27 | -- | -- | -- |
| Cassava Sciences Inc | 0.00 | -106.03m | 100.96m | 30.00 | -- | 1.24 | -- | -- | -2.20 | -2.20 | 0.00 | 1.69 | 0.00 | -- | -- | 0.00 | -59.99 | -28.22 | -85.37 | -29.72 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 74.96 | -- | 41.75 | -- |
| Turn Therapeutics Inc | -100.00bn | -100.00bn | 103.35m | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Goldenwell Biotech Inc | 62.50k | -75.13k | 103.95m | -- | -- | -- | -- | 1,663.20 | -0.0007 | -0.0007 | 0.0006 | -0.001 | 0.3126 | 0.00 | -- | -- | -37.58 | -95.49 | -41.82 | -110.12 | 100.00 | 52.18 | -120.21 | -2,064.27 | 1.16 | -4.11 | 124.14 | -- | -92.39 | -13.55 | -12.05 | -- | -- | -- |
| Korro Bio Inc | 7.37m | -88.42m | 105.19m | 87.00 | -- | 1.06 | -- | 14.27 | -9.42 | -9.42 | 0.7855 | 10.54 | 0.0364 | -- | 1.36 | 70,875.00 | -43.65 | -- | -46.92 | -- | -- | -- | -1,199.53 | -- | -- | -- | 0.00 | -- | -- | -- | -2.97 | -- | -- | -- |
| Agenus Inc | 106.83m | -35.38m | 105.53m | 316.00 | -- | -- | -- | 0.9879 | -2.09 | -2.09 | 3.94 | -8.35 | 0.4523 | -- | 286.79 | 338,066.50 | -16.63 | -58.29 | -- | -140.29 | 98.93 | 97.31 | -36.77 | -125.67 | -- | -1.17 | 6.78 | -- | -33.81 | -7.17 | 7.54 | -- | -34.16 | -- |
| Citius Oncology Inc | 0.00 | -24.76m | 107.70m | -- | -- | 2.27 | -- | -- | -0.3400 | -0.3400 | 0.00 | 0.5372 | 0.00 | -- | -- | -- | -26.72 | -- | -48.02 | -- | -- | -- | -- | -- | 0.1062 | -129.48 | 0.0781 | -- | -- | -- | -17.08 | -- | -- | -- |
| Cardiff Oncology Inc | 501.00k | -50.45m | 107.78m | 32.00 | -- | 2.20 | -- | 215.12 | -0.7976 | -0.7976 | 0.0079 | 0.7272 | 0.0079 | -- | 1.15 | 15,656.25 | -79.61 | -32.23 | -101.41 | -34.83 | -- | -- | -10,064.27 | -7,588.71 | -- | -- | 0.00 | -- | 39.96 | 22.80 | -9.62 | -- | 3.42 | -- |
Data as of Feb 13 2026. Currency figures normalised to Artiva Biotherapeutics Inc's reporting currency: US Dollar USD
50.34%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RA Capital Management LPas of 30 Sep 2025 | 9.85m | 40.44% |
| Citadel Advisors LLCas of 30 Sep 2025 | 671.07k | 2.75% |
| Franklin Advisers, Inc.as of 31 Dec 2025 | 520.33k | 2.14% |
| Millennium Management LLCas of 30 Sep 2025 | 262.16k | 1.08% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 211.62k | 0.87% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 207.69k | 0.85% |
| Wellington Management Co. LLPas of 30 Sep 2025 | 194.11k | 0.80% |
| Citadel Securities LLCas of 30 Sep 2025 | 127.32k | 0.52% |
| Renaissance Technologies LLCas of 31 Dec 2025 | 116.20k | 0.48% |
| Geode Capital Management LLCas of 31 Dec 2025 | 101.12k | 0.42% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
